MeSH D000075222 - essential hypertension
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D006973:Hypertension
D000075222:Â
Essential hypertension
D000092244:Isolated systolic hypertension
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Allergan | Telmisartan, Hydrochlorothiazide | Actelsar |  | 2013-03-13 |  |  |
| Nova Laboratories | Spironolactone | Qaialdo |  | 2023-05-26 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
62%16/26
Phase 2
66%19/29
Phase 3
71%20/28
Approved: 1Overall Success rate: 29%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use